How many employees work at Immunovant?
Illinois Tool Works Inc. (ITW) is a Fortune 250 global multinational manufacturer of specialized industrial equipment, fasteners, consumables, and related component systems. According to official corporate disclosures and workforce metrics, the enterprise employs approximately 43,000 people worldwide. This diverse industrial workforce operates across decentralized business units spanning 55 countries, with primary employee concentrations located in North America, Europe, and the Asia-Pacific region, comprising mechanical engineers, product designers, manufacturing crews, and global sales professionals.
Related FAQs
Equity research reports covering Immunovant generally assign favorable buy ratings, driven by its promising clinical-stage immunological pipeline targeting autoimmune diseases with novel antibody technologies.
Evaluating Immunovant as a long-term investment involves assessing its clinical-stage immunological pipeline targeting autoimmune diseases with novel monoclonal antibody therapies.
Immunovant is a clinical-stage immunology company focused on developing innovative, targeted antibody therapies for patients suffering from severe, IgG-mediated autoimmune diseases.
IMVT is the stock ticker symbol for Immunovant, Inc., a clinical-stage immunology company focused on developing innovative treatments for autoimmune diseases.
Immunovant, Inc. (IMVT) does not currently provide a dividend to its shareholders.
Market forecasts for Immunovant (IMVT) indicate a potential price target of approximately $39.39 by the end of 2026. Looking further into the future, long-term projections suggest the stock price may reach $22.66 by the end of 2029.